UBS Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

UBS Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-900	Closed	-$115K	–	10568
2021 Q4	$115K	Hold	900	–	–	﹤0.01%	6184
2021 Q3	$117K	Sell	900 -14,200	-94%	-$2.15M	﹤0.01%	5720
2021 Q2	$2.68M	Hold	15,100	–	–	﹤0.01%	3290
2021 Q1	$2.48M	Buy	+15,100	New	+$2.48M	﹤0.01%	3341
2017 Q1	–	Sell	-50,000	Closed	-$5.45M	–	7787
2016 Q4	$5.45M	Buy	50,000 +2,500	+5%	+$278K	﹤0.01%	2016
2016 Q3	$5.77M	Buy	47,500 +10,000	+27%	+$1.35M	﹤0.01%	1893
2016 Q2	$5.3M	Hold	37,500	–	–	﹤0.01%	1907
2016 Q1	$4.9M	Sell	37,500 -10,200	-21%	-$1.27M	﹤0.01%	1882
2015 Q4	$6.71M	Sell	47,700 -40,000	-46%	-$5.54M	﹤0.01%	1721
2015 Q3	$11.6M	Buy	87,700 +45,000	+105%	+$7.75M	0.01%	1256
2015 Q2	$7.52M	Buy	42,700 +42,500	+21,250%	+$7.63M	0.01%	1704
2015 Q1	$35K	Sell	200 -13,600	-99%	-$2.33M	﹤0.01%	6388
2014 Q4	$2.26M	Buy	+13,800	New	+$2.29M	﹤0.01%	2783

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

UBS Group's JAZZ Position: Q1 2026 in Review

UBS Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 24% in Q1 2026, selling an estimated $20.2M and leaving 357,203 shares worth $67.5M. The position accounts for 0.01% of the portfolio, ranked #1350.

UBS Group first reported a position in JAZZ in Q4 2014 and has held it in 46 quarters since. The position peaked at $80.4M in Q4 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

UBS Group held 357,203 shares of Jazz Pharmaceuticals worth $67.5M as of Q1 2026.
UBS Group sold 115,749 Jazz Pharmaceuticals shares in Q1 2026, an estimated $20.2M.
Jazz Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1350 holding.
UBS Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Jazz Pharmaceuticals position peaked at $80.4M in Q4 2025.
571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.